A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy

Phase 2 Completed 159 enrolled Amgen

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapy.

Timeline

Start: 2010-09
Primary completion: 2011-07
Completion: 2011-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CCX354	Small molecule	100 mg	—
Subject	CCX354	Small molecule	200 mg	—

A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy

Summary

Timeline

Drugs

Indications